Wuziyuye Decoction for type-II diabetes mellitus with qi-yin deficiency complicated by asthenospermia: A randomized controlled trial.
- Author:
Yi YU
1
;
Gang XU
2
;
Ping JIN
1
;
Hong-Ping SHEN
3
;
Ke-Rong WU
4
;
Li-Qi XU
5
;
Xue-Qin CHEN
1
;
Xue-Jun SHANG
6
Author Information
1. Center of Reproductive Medicine, The First Hospital Affiliated to Ningbo University, Ningbo, Zhejiang 315010, China.
2. Department of Endocrinology, The First Hospital Affiliated to Ningbo University, Ningbo, Zhejiang 315010, China.
3. Department of Traditional Chinese Medicine, The First Hospital Affiliated to Ningbo University, Ningbo, Zhejiang 315010, China.
4. Department of Urology, The First Hospital Affiliated to Ningbo University, Ningbo, Zhejiang 315010, China.
5. Center of Reproductive Medicine, The 906th Hospital of PLA Joint Logistics Support Force, Ningbo, Zhejiang 315000, China.
6. Department of Urology, Jinling Hospital Affiliated to Nanjing University School of Medicine / General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210018, China .
- Publication Type:English Abstract
- Keywords:
male infertility;
asthenospermia;
diabetes mellitus;
Wuziyuye Decoction;
qi-yin deficiency syndrome
- MeSH:
Humans;
Drugs, Chinese Herbal/therapeutic use*;
Male;
Asthenozoospermia/complications*;
Diabetes Mellitus, Type 2/drug therapy*;
Yin Deficiency/complications*;
Adult;
Medicine, Chinese Traditional;
Sperm Motility;
Qi;
Female;
Pregnancy
- From:
National Journal of Andrology
2024;30(12):1122-1127
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical efficacy and safety of Wuziyuye Decoction in the treatment of type-II diabetes mellitus (DM) with qi-yin deficiency complicated by asthenospermia.
METHODS:We selected 100 cases of type-II DM with qi-yin deficiency complicated by asthenospermia treated in the First Hospital Affiliated to Ningbo University from January 2023 to March 2024, and randomly assigned them to receive Wuziyuye Decoction (the trial group, n = 50) and oral L-carnitine solution (the control group, n = 50) in addition to Western medicine to reduce fasting blood glucose to normal in both groups. After 12 weeks of medication, we followed up the patients for 24 weeks, obtained their semen parameters, traditional Chinese medicine (TCM) syndrome scores and levels of reproductive hormones, and the clinical pregnancy outcomes of their partners, followed by comparison of the data collected between the two groups before and after treatment.
RESULTS:After 12 weeks of treatment, the trial group showed significant improvement over the baseline in the percentage of progressive motility (PR%) (［35.5±6.1］% vs ［18.0±4.2］%, P<0.05), sperm concentration (［54.0±33.4］ vs ［40.0±36.1］ × 10⁶/ml, P<0.05), and TCM syndrome score (4.5±2.3 vs 18.5±5.2, P<0.05), but no statistically significant difference in the semen volume (［2.85±0.36］ vs ［2.84±0.59］ ml, P>0.05), while the controls exhibited markedly improved percentage of PR% (［29.5±6.2］% vs ［18.5±4.5］%, P<0.05) and sperm concentration (［45.0±34.1］ vs ［42.0±38.3］ × 10⁶/ml, P<0.05), but no statistically significant difference in the semen volume (［3.04±0.89］ vs ［2.90±0.78］ ml, P>0.05) and TCM syndrome score (17.2±4.5 vs 17.8±4.8, P>0.05). The patients treated with Wuziyuye Decoction achieved even more significant improvement than the controls in the percentage of PR%, sperm concentration and TCM syndrome score (P<0.05), but there were no statistically significant differences in the reproductive hormone levels and clinical pregnancy outcomes between the two groups of patients after treatment (P>0.05). And no severe adverse reactions were observed in either group.
CONCLUSION:Wuziyuye Decoction is safe and effective for the treatment of type-II DM with qi-yin deficiency complicated by asthenospermia by improving the sperm motility and concentration of the patient.
